We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The neuropathic pain market is the most valuable segment within the pain indications and was valued at $10.8 billion in 2020 globally. It is forecast to reach $25.2 billion by 2027 at a compound annual growth rate (CAGR) of 12.9 per cent.